IL-6 for PMR SPARE and SEMAPORE (Toci), SAPHYR (Sari) 2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off Robert Spiera @RheumNow #RNL2023 https://t.co/VtzW01Ez7D https://t.co/P6oUQvmDXH